{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T00:26:03Z","timestamp":1790382363289,"version":"4.1.0"},"reference-count":269,"publisher":"FapUNIFESP (SciELO)","issue":"2 suppl 1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["An. Bras. Dermatol."],"DOI":"10.1590\/abd1806-4841.2019940211","type":"journal-article","created":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T19:49:52Z","timestamp":1559418592000},"page":"76-107","source":"Crossref","is-referenced-by-count":30,"title":["Diagnostic and therapeutic guidelines for plaque psoriasis - Brazilian Society of Dermatology"],"prefix":"10.1590","volume":"94","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7192-5161","authenticated-orcid":false,"given":"Marcelo","family":"Arnone","sequence":"first","affiliation":[{"name":"Universidade de S\u00e3o Paulo, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8671-6680","authenticated-orcid":false,"given":"Maria Denise Fonseca","family":"Takahashi","sequence":"additional","affiliation":[{"name":"Universidade de S\u00e3o Paulo, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0407-538X","authenticated-orcid":false,"given":"Andr\u00e9 Vicente Esteves de","family":"Carvalho","sequence":"additional","affiliation":[{"name":"Hospital Moinhos de Vento, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8597-5207","authenticated-orcid":false,"given":"Wanderley Marques","family":"Bernardo","sequence":"additional","affiliation":[{"name":"Universidade de S\u00e3o Paulo, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3296-5232","authenticated-orcid":false,"given":"Aline Lopes","family":"Bressan","sequence":"additional","affiliation":[{"name":"Universidade do Estado do Rio de Janeiro, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7414-3395","authenticated-orcid":false,"given":"Andrea Machado Coelho","family":"Ramos","sequence":"additional","affiliation":[{"name":"Universidade Federal de Minas Gerais, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2550-1341","authenticated-orcid":false,"given":"Aripuan\u00e3 Cob\u00e9rio","family":"Terena","sequence":"additional","affiliation":[{"name":"Center of Reference in Phototherapy and Cutaneous Photobiology, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8157-7658","authenticated-orcid":false,"given":"Cacilda da Silva","family":"Souza","sequence":"additional","affiliation":[{"name":"Universidade de S\u00e3o Paulo, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1303-5419","authenticated-orcid":false,"given":"Daniel Holthausen","family":"Nunes","sequence":"additional","affiliation":[{"name":"Universidade Federal de Santa Catarina, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6156-6097","authenticated-orcid":false,"given":"Maria Cec\u00edlia de Carvalho","family":"Bortoletto","sequence":"additional","affiliation":[{"name":"Faculdade de Medicina do ABC, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8594-200X","authenticated-orcid":false,"given":"Maria de F\u00e1tima Santos Paim de","family":"Oliveira","sequence":"additional","affiliation":[{"name":"DERMAPP - Dermatology Clinic, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7888-0154","authenticated-orcid":false,"given":"Jane Marcy","family":"Neff\u00e1","sequence":"additional","affiliation":[{"name":"Universidade Federal Fluminense, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7981-9398","authenticated-orcid":false,"given":"Luciana Cristina","family":"Fieri","sequence":"additional","affiliation":[{"name":"Universidade de Mogi das Cruzes, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4698-2009","authenticated-orcid":false,"given":"Luna","family":"Azulay-Abulafia","sequence":"additional","affiliation":[{"name":"Universidade do Estado do Rio de Janeiro, Brazil; Santa Casa de Miseric\u00f3rdia do Rio de Janeiro, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1055-0597","authenticated-orcid":false,"given":"Paulo Ant\u00f4nio Oldani","family":"Felix","sequence":"additional","affiliation":[{"name":"Hospital Federal dos Servidores do Estado, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9170-932X","authenticated-orcid":false,"given":"Renata Ferreira","family":"Magalhaes","sequence":"additional","affiliation":[{"name":"Universidade Estadual de Campinas, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0165-3831","authenticated-orcid":false,"given":"Ricardo","family":"Romiti","sequence":"additional","affiliation":[{"name":"Universidade de S\u00e3o Paulo, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7594-620X","authenticated-orcid":false,"given":"Tatiana Jerez","family":"Jaime","sequence":"additional","affiliation":[{"name":"Cl\u00ednica Jerez Dermatologia, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"530","published-online":{"date-parts":[[2019,4]]},"reference":[{"key":"ref1","series-title":"Projeto Diretrizes AMB: Psor\u00edase","author":"Arnone M"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1111\/j.1365-2230.2006.02305.x","article-title":"Interobserver reliability of the Nail Psoriasis Severity Index. Clin Exp Dermatol","volume":"32","author":"Aktan S","year":"2007","journal-title":"Clin Exp Dermatol"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.1111\/j.1468-3083.2009.03563.x","article-title":"What are the best outcome measures for assessing quality of life in plaque type psoriasis? A systematic review of the literature","volume":"24","author":"Bronsard V","year":"2010","journal-title":"JJ Eur Acad Dermatol Venereol"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1038\/jid.2013.138","article-title":"The Simplified Psoriasis Index (SPI): A Practical Tool for Assessing Psoriasis","volume":"133","author":"Chularojanamontri L","year":"2013","journal-title":"J Invest Dermatol"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1016\/j.jaad.2017.06.162","article-title":"Assessing clinical response and defining minimal disease activity in plaque psoriasis with the Physician Global Assessment and body surface area (PGA \u00d7 BSA) composite tool: An analysis of apremilast phase 3 ESTEEM data","volume":"77","author":"Gottlieb AB","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.jaad.2004.02.021","article-title":"Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial","volume":"51","author":"Gottlieb AB","year":"2004","journal-title":"J Am Acad Dermatol"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.jaad.2004.04.012","article-title":"Evaluating psoriasis with Psoriasis Area and Severity Index, Psoriasis Global Assessment, and Lattice System Physician's Global Assessment","volume":"51","author":"Langley RG","year":"2004","journal-title":"J Am Acad Dermatol"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/j.1468-3083.2011.04000.x","article-title":"Skin pain and skin discomfort is associated with quality of life in patients with psoriasis","volume":"26","author":"Ljosaa TM","year":"2012","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/acr.20691","article-title":"Is the Nail Psoriasis Severity Index reliable in the assessment of nail psoriasis by rheumatologists?","volume":"64","author":"Lubrano E","year":"2012","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1080\/000155500300012873","article-title":"Health-related quality of life in patients with psoriasis and atopic dermatitis measured with SF-36, DLQI and a subjective measure of disease activity","volume":"80","author":"Lundberg L","year":"2000","journal-title":"Acta Derm Venereol"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1111\/jdv.12106","article-title":"Psoriasis Area Severity Index (PASI) and the Dermatology Life Quality Index (DLQI): the correlation between disease severity and psychological burden in patients treated with biological therapies","volume":"28","author":"Mattei PL","year":"2014","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1016\/S0140-6736(05)67566-6","article-title":"Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial","volume":"366","author":"Reich K","year":"2005","journal-title":"Lancet"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1067\/S0190-9622(03)00910-1","article-title":"Nail Psoriasis Severity Index: a useful tool for evaluation of nail psoriasis","volume":"49","author":"Rich P","year":"2003","journal-title":"J Am Acad Dermatol"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.jaad.2011.01.022","article-title":"Physician Global Assessment (PGA) and Psoriasis Area and Severity Index (PASI): why do both? A systematic analysis of randomized controlled trials of biologic agents for moderate to severe plaque psoriasis","volume":"66","author":"Robinson A","year":"2012","journal-title":"J Am Acad Dermatol"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/j.jaad.2013.07.040","article-title":"Product of the Physician Global Assessment and body surface area: a simple static measure of psoriasis severity in a longitudinal cohort","volume":"69","author":"Walsh JA","year":"2013","journal-title":"J Am Acad Dermatol"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/j.1468-3083.2009.03562.x","article-title":"What are the best outcome measures for assessing plaque psoriasis severity? A systematic review of the literature","volume":"24","author":"Puzenat E","year":"2010","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref17","first-page":"33","article-title":"A Case-control Study to Evaluate the Prevalence of Nonalcoholic Fatty Liver Disease Among Patients with Moderate-to-severe Psoriasis","volume":"11","author":"Awosika O","year":"2018","journal-title":"J Clin Aesthet Dermatol"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1590\/abd1806-4841.20142874","article-title":"Comorbidities and cardiovascular risk factors in patients with psoriasis","volume":"89","author":"Baeta IG","year":"2014","journal-title":"An Bras Dermatol"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1111\/j.1365-2133.2009.09398.x","article-title":"Coeliac disease associated with psoriasis","volume":"161","author":"Birkenfeld S","year":"2009","journal-title":"Br J Dermatol"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1111\/jdv.14472","article-title":"Psoriasis and migraine","volume":"32","author":"Capo A","year":"2018","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref21","article-title":"Incidence of Pulmonary Arterial Hypertension in Patients with Psoriasis: A Retrospective Cohort Study","volume":"21","author":"Choi YM","year":"2017","journal-title":"Perm J"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1111\/j.1468-3083.2008.02636.x","article-title":"Psoriasis and diabetes: a population-based cross-sectional study","volume":"22","author":"Cohen AD","year":"2008","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"23","DOI":"10.2340\/00015555-0741","article-title":"Psoriasis and hypertension: a case-control study","volume":"90","author":"Cohen AD","year":"2010","journal-title":"Acta Derm Venereol"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1001\/jamadermatol.2015.3605","article-title":"Psoriasis and the Risk of Depression in the US Population: National Health and Nutrition Examination Survey 2009-2012","volume":"152","author":"Cohen BE","year":"2016","journal-title":"JAMA Dermatol"},{"key":"ref25","first-page":"5","article-title":"Psoriasis and comorbidities: general practitioners' awareness","volume":"27","author":"Costa-Silva M","year":"2018","journal-title":"Acta Dermatovenerol Alp Pannonica Adriat."},{"key":"ref26","doi-asserted-by":"crossref","first-page":"e93","DOI":"10.1111\/ajd.12577","article-title":"Factors influencing cardiometabolic risk profile in patients with psoriasis","volume":"59","author":"Curc\u00f3 N","year":"2018","journal-title":"Australas J Dermatol"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1038\/jid.2014.530","article-title":"The psychological burden of skin diseases: a cross-sectional multicenter study among dermatological out-patients in 13 European countries","volume":"135","author":"Dalgard FJ","year":"2015","journal-title":"J Invest Dermatol"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1111\/ddg.12193","article-title":"Metabolic syndrome in untreated patients with psoriasis: case-control study","volume":"11","author":"Damevska K","year":"2013","journal-title":"J Dtsch Dermatol Ges"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1111\/bjd.14032","article-title":"Risk of depression in women with psoriasis: a cohort study","volume":"173","author":"Dommasch ED","year":"2015","journal-title":"Br J Dermatol"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1111\/j.1365-2133.2008.08749.x","article-title":"Psoriasis and chronic obstructive pulmonary disease: a case-control study","volume":"159","author":"Dreiher J","year":"2008","journal-title":"Br J Dermatol"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1080\/09546630802225702","article-title":"Cardiovascular risk factors in high-need psoriasis patients and its implications for biological therapies","volume":"20","author":"Driessen RJ","year":"2009","journal-title":"J Dermatolog Treat"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1111\/bjd.13778","article-title":"Association between depression and risk of atrial fibrillation and stroke in patients with psoriasis: a Danish nationwide cohort study","volume":"173","author":"Egeberg A","year":"2015","journal-title":"Br J Dermatol"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.jaad.2015.08.039","article-title":"Increased risk of migraine in patients with psoriasis: A Danish nationwide cohort study","volume":"73","author":"Egeberg A","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1097\/MIB.0000000000001169","article-title":"Prevalence and Phenotype of Concurrent Psoriasis and Inflammatory Bowel Disease","volume":"23","author":"Eppinga H","year":"2017","journal-title":"Inflamm Bowel Dis"},{"key":"ref35","first-page":"874","article-title":"Economic and Comorbidity Burden Among Patients with Moderate-to-Severe Psoriasis","volume":"21","author":"Feldman SR","year":"2015","journal-title":"J Manag Care Spec Pharm"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.jhep.2009.04.020","article-title":"Non-alcoholic fatty liver disease in patients with chronic plaque psoriasis","volume":"51","author":"Gisondi P","year":"2009","journal-title":"J Hepatol"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/jebm.12018","article-title":"Understanding GRADE: an introduction","volume":"6","author":"Goldet G","year":"2013","journal-title":"J J Evid Based Med"},{"key":"ref38","first-page":"843","article-title":"Increased prevalence of psychiatric disorders and health care-associated costs among patients with moderate-to-severe psoriasis","volume":"10","author":"Han C","year":"2011","journal-title":"J Drugs Dermatol"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.amepre.2014.02.012","article-title":"Prevalence of psoriasis among adults in the U.S.: 2003-2006 and 2009-2010 National Health and Nutrition Examination Surveys","volume":"47","author":"Helmick CG","year":"2014","journal-title":"Am J Prev Med."},{"key":"ref40","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1016\/0190-9622(95)91336-X","article-title":"Disease concomitance in psoriasis","volume":"32","author":"Henseler T","year":"1995","journal-title":"J Am Acad Dermatol"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","article-title":"Assessing the quality of reports of randomized clinical trials: is blinding necessary?","volume":"17","author":"Jadad AR","year":"1996","journal-title":"Control Clin Trials"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"449","DOI":"10.2340\/0001555572449450","article-title":"One-minute dithranol therapy in psoriasis: a placebo-controlled paired comparative study","volume":"72","author":"Jekler J","year":"1992","journal-title":"Acta Derm Venereol"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"125","DOI":"10.4103\/0972-6748.181724","article-title":"Psychiatric morbidity and quality of life in skin diseases: A comparison of alopecia areata and psoriasis","volume":"24","author":"Karia SB","year":"2015","journal-title":"Ind Psychiatry J"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.1093\/eurheartj\/ehv185","article-title":"Increased risk of aortic valve stenosis in patients with psoriasis: a nationwide cohort study","volume":"36","author":"Khalid U","year":"2015","journal-title":"Eur Heart J"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.2337\/dc12-2330","article-title":"Psoriasis and new-onset diabetes: a Danish nationwide cohort study","volume":"36","author":"Khalid U","year":"2013","journal-title":"Diabetes Care"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"440","DOI":"10.5021\/ad.2013.25.4.440","article-title":"An observational study on the obesity and metabolic status of psoriasis patients","volume":"25","author":"Kim CR","year":"2013","journal-title":"Ann Dermatol"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.jaad.2011.11.948","article-title":"Risks of developing psychiatric disorders in pediatric patients with psoriasis","volume":"67","author":"Kimball AB","year":"2012","journal-title":"J Am Acad Dermatol"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.ajp.2012.10.005","article-title":"Psychiatric morbidity in pemphigus and psoriasis: a comparative study from India","volume":"6","author":"Kumar V","year":"2013","journal-title":"Asian J Psychiatr"},{"key":"ref49","first-page":"891","article-title":"The risk of depression, anxiety, and suicidality in patients with psoriasis: a population-based cohort study","volume":"146","author":"Kurd SK","year":"2010","journal-title":"Arch Dermatol"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"434","DOI":"10.4103\/0253-7176.168587","article-title":"A Cross-sectional Study of Prevalence and Implications of Depression and Anxiety in Psoriasis","volume":"37","author":"Lakshmy S","year":"2015","journal-title":"Indian J Psychol Med"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"353","DOI":"10.4103\/0019-5154.100474","article-title":"Prevalence of metabolic syndrome in South Indian patients with psoriasis vulgaris and the relation between disease severity and metabolic syndrome: a hospital-based case-control study","volume":"57","author":"Madanagobalane S","year":"2012","journal-title":"Indian J Dermatol"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1111\/j.1468-3083.2010.03856.x","article-title":"Metabolic syndrome in Tunisian psoriatic patients: prevalence and determinants","volume":"25","author":"Mebazaa A","year":"2011","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref53","doi-asserted-by":"crossref","first-page":"e518","DOI":"10.1111\/ijd.12186","article-title":"Psoriasis and comorbidities in a southern Brazilian population: a case-control study","volume":"53","author":"Menegon DB","year":"2014","journal-title":"Int J Dermatol"},{"key":"ref54","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1590\/abd1806-4841.20175178","article-title":"Prevalence of metabolic syndrome in patients with psoriasis: a hospital-based cross-sectional study","volume":"92","author":"Milcic D","year":"2017","journal-title":"An Bras Dermatol"},{"key":"ref55","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1007\/s10508-016-0757-8","article-title":"Prevalence and Associated Factors of Erectile Dysfunction in Patients With Moderate to Severe Psoriasis and Healthy Population: A Comparative Study Considering Physical and Psychological Factors","volume":"45","author":"Molina-Leyva A","year":"2016","journal-title":"Arch Sex Behav"},{"key":"ref56","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.jaad.2006.08.040","article-title":"Prevalence of cardiovascular risk factors in patients with psoriasis","volume":"55","author":"Neimann AL","year":"2006","journal-title":"J Am Acad Dermatol"},{"key":"ref57","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1111\/1346-8138.13761","article-title":"Epidemiology and cardiovascular comorbidities in patients with psoriasis: A Korean nationwide population-based cohort study","volume":"44","author":"Oh EH","year":"2017","journal-title":"J Dermatol"},{"key":"ref58","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1038\/jid.2015.87","article-title":"Psoriasis and the Risk of Major Cardiovascular Events: Cohort Study Using the Clinical Practice Research Datalink","volume":"135","author":"Parisi R","year":"2015","journal-title":"J Invest Dermatol"},{"key":"ref59","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1590\/abd1806-4841.20186397","article-title":"Metabolic syndrome, C-reactive protein and cardiovascular risk in psoriasis patients: a cross-sectional study","volume":"93","author":"Paschoal RS","year":"2018","journal-title":"An Bras Dermatol"},{"key":"ref60","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1080\/09546630500335977","article-title":"The comorbid state of psoriasis patients in a university dermatology practice","volume":"16","author":"Pearce DJ","year":"2005","journal-title":"J Dermatolog Treat"},{"key":"ref61","series-title":"Levels of Evidence and Grades of Recommendation","author":"Phillips B","year":"2001"},{"key":"ref62","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.jaad.2005.11.1103","article-title":"Prevalence and correlates of suicidal ideation among patients with skin disease","volume":"54","author":"Picardi A","year":"2006","journal-title":"J Am Acad Dermatol"},{"key":"ref63","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.jad.2016.11.045","article-title":"Depressiveness, measured with Beck Depression Inventory, in patients with psoriasis","volume":"209","author":"Pietrzak D","year":"2017","journal-title":"J Affect Disord"},{"key":"ref64","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1080\/13651501.2017.1301482","article-title":"Psychiatric comorbidity and suicidal ideation in psoriasis, melanoma and allergic disorders","volume":"21","author":"Pompili M","year":"2017","journal-title":"Int J Psychiatry Clin Pract"},{"key":"ref65","doi-asserted-by":"crossref","first-page":"415","DOI":"10.2340\/00015555-1074","article-title":"A case-control study on family dysfunction in patients with alopecia areata, psoriasis and atopic dermatitis","volume":"91","author":"Poot F","year":"2011","journal-title":"Acta Derm Venereol"},{"key":"ref66","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1001\/archdermatol.2009.94","article-title":"Association of psoriasis with coronary artery, cerebrovascular, and peripheral vascular diseases and mortality","volume":"145","author":"Prodanovich S","year":"2009","journal-title":"Arch Dermatol"},{"key":"ref67","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1111\/jdv.13813","article-title":"Prevalence and comorbidities in adults with psoriasis compared to atopic eczema","volume":"31","author":"Radtke MA","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref68","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1111\/apt.13042","article-title":"The prevalence of NAFLD and NASH among patients with psoriasis in a tertiary care dermatology and rheumatology clinic","volume":"41","author":"Roberts KK","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"key":"ref69","first-page":"WC06","article-title":"Association of Metabolic Syndrome in Chronic Plaque Psoriasis Patients and their Correlation with Disease Severity, Duration and Age: A Case Control Study from Western Maharashtra","volume":"11","author":"Salunke AS","year":"2017","journal-title":"J Clin Diagn Res"},{"key":"ref70","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1111\/bjd.15243","article-title":"Prevalence of alexithymia in patients with psoriasis and its association with disease burden: a multicentre observational study","volume":"176","author":"Sampogna F","year":"2017","journal-title":"Br J Dermatol"},{"key":"ref71","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1111\/1346-8138.12465","article-title":"Comorbidities and health-related quality of life in Spanish patients with moderate to severe psoriasis: a cross-sectional study (Arizona study)","volume":"41","author":"Sanchez-Carazo JL","year":"2014","journal-title":"J Dermatol"},{"key":"ref72","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1111\/j.1468-3083.2009.03537.x","article-title":"Psoriasis is independently associated with psychiatric morbidity and adverse cardiovascular risk factors, but not with cardiovascular events in a population-based sample","volume":"24","author":"Schmitt J","year":"2010","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref73","doi-asserted-by":"crossref","first-page":"792968","DOI":"10.1155\/2015\/792968","article-title":"Psoriasis and Diabetes: A Multicenter Study in 222078 Type 2 Diabetes Patients Reveals High Levels of Depression","volume":"2015","author":"Schwandt A","year":"2015","journal-title":"J Diabetes Res"},{"key":"ref74","doi-asserted-by":"crossref","first-page":"287.e4","DOI":"10.1016\/j.jaad.2017.03.037","article-title":"Real-world burden of comorbidities in US patients with psoriasis","volume":"77","author":"Shah K","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"ref75","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.jaad.2006.09.017","article-title":"The association between psoriasis, diabetes mellitus, and atherosclerosis in Israel: a case-control study","volume":"56","author":"Shapiro J","year":"2007","journal-title":"J Am Acad Dermatol"},{"key":"ref76","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/s00403-006-0703-z","article-title":"Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis","volume":"298","author":"Sommer DM","year":"2006","journal-title":"Arch Dermatol Res"},{"key":"ref77","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jdermsci.2011.03.002","article-title":"Epidemiology and comorbidities of psoriasis patients in a national database in Taiwan","volume":"63","author":"Tsai TF","year":"2011","journal-title":"J Dermatol Sci"},{"key":"ref78","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1111\/jdv.12028","article-title":"Co-morbidities in psoriasis: a hospital-based case-control study","volume":"27","author":"Tseng HW","year":"2013","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref79","first-page":"70","article-title":"Psychosomatic aspects in patients with dermatologic diseases","volume":"243","author":"Tsintsadze N","year":"2015","journal-title":"Georgian Med News"},{"key":"ref80","first-page":"35","article-title":"Immune-mediated inflammatory diseases and other comorbidities in patients with psoriasis: baseline characteristics of patients in the AQUILES study","volume":"106","author":"Vanaclocha F","year":"2015","journal-title":"Actas Dermosifiliogr"},{"key":"ref81","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.jaad.2013.10.044","article-title":"Psoriasis is independently associated with nonalcoholic fatty liver disease in patients 55 years old or older: Results from a population-based study","volume":"70","author":"van der Voort EA","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"ref82","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/0005-2744(76)90015-2","article-title":"Partial purification and characterization of post-proline cleaving enzyme: enzymatic inactivation of neurohypophyseal hormones by kidney preparations of various species","volume":"422","author":"Walter R","year":"1976","journal-title":"Biochim Biophys Acta"},{"key":"ref83","series-title":"The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses","author":"Wells G"},{"key":"ref84","article-title":"The Prevalence of Nonalcoholic Fatty Liver Disease and Related Metabolic Comorbidities Was Associated with Age at Onset of Moderate to Severe Plaque Psoriasis: A Cross-Sectional Study","volume":"12","author":"Xu X","year":"2017","journal-title":"PLoS One"},{"key":"ref85","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1111\/j.1365-2133.2011.10494.x","article-title":"Medical comorbidity associated with psoriasis in adults: a population-based study","volume":"165","author":"Yang YW","year":"2011","journal-title":"Br J Dermatol"},{"key":"ref86","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1001\/jamadermatol.2013.5015","article-title":"Psoriasis severity and the prevalence of major medical comorbidity: a population-based study","volume":"149","author":"Yeung H","year":"2013","journal-title":"JAMA Dermatol"},{"key":"ref87","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/joim.12002","article-title":"Prevalence and extent of subclinical atherosclerosis in patients with psoriasis","volume":"273","author":"Yiu KH","year":"2013","journal-title":"J Intern Med"},{"key":"ref88","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/s00403-017-1741-4","article-title":"Dermatological comorbidity in psoriasis: results from a large-scale cohort of employees","volume":"309","author":"Zander N","year":"2017","journal-title":"Arch Dermatol Res"},{"key":"ref89","first-page":"357","article-title":"An intra-individual randomized safety and efficacy comparison of clobetasol propionate 0.05% spray and its vehicle in the treatment of plaque psoriasis","volume":"5","author":"Beutner K","year":"2006","journal-title":"J Drugs Dermatol"},{"key":"ref90","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1111\/j.1365-2133.2004.06174.x","article-title":"Better medication adherence results in greater improvement in severity of psoriasis","volume":"151","author":"Carroll CL","year":"2004","journal-title":"Br J Dermatol"},{"key":"ref91","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1001\/archderm.141.1.43","article-title":"Topical tacrolimus ointment combined with 6% salicylic acid gel for plaque psoriasis treatment","volume":"141","author":"Carroll CL","year":"2005","journal-title":"Arch Dermatol"},{"key":"ref92","first-page":"201","article-title":"Clobetasol propionate lotion in the treatment of moderate to severe plaque-type psoriasis","volume":"74","author":"Decroix J","year":"2004","journal-title":"Cutis"},{"key":"ref93","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1080\/00015550252948194","article-title":"A new calcipotriol\/betamethasone formulation with rapid onset of action was superior to monotherapy with betamethasone dipropionate or calcipotriol in psoriasis vulgaris","volume":"82","author":"Douglas WS","year":"2002","journal-title":"Acta Derm Venereol"},{"key":"ref94","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/0190-9622(92)70299-U","article-title":"Efficacy and safety of calcipotriol (MC 903) ointment in psoriasis vulgaris. A randomized, double-blind, right\/left comparative, vehicle-controlled study","volume":"27","author":"Dubertret L","year":"1992","journal-title":"J Am Acad Dermatol"},{"key":"ref95","doi-asserted-by":"crossref","first-page":"261","DOI":"10.2165\/11630710-000000000-00000","article-title":"Efficacy and safety of calcipotriene 0.005% foam for the treatment of plaque-type psoriasis: results of two multicenter, randomized, double-blind, vehicle-controlled, phase III clinical trials","volume":"13","author":"Feldman SR","year":"2012","journal-title":"Am J Clin Dermatol"},{"key":"ref96","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1046\/j.1365-4362.2000.00986-4.x","article-title":"Clobetasol propionate foam 0.05%: a novel vehicle with enhanced delivery","volume":"39","author":"Franz TJ","year":"2000","journal-title":"Int J Dermatol"},{"key":"ref97","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1177\/120347540300700301","article-title":"The efficacy and tolerability of clobetasol propionate foam 0.05% in the treatment of mild to moderate plaque-type psoriasis of nonscalp regions","volume":"7","author":"Gottlieb AB","year":"2003","journal-title":"J Cutan Med Surg"},{"key":"ref98","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1046\/j.1365-2133.2002.04967.x","article-title":"Efficacy and safety of a new combination of calcipotriol and betamethasone dipropionate (once or twice daily) compared to calcipotriol (twice daily) in the treatment of psoriasis vulgaris: a randomized, double-blind, vehicle-controlled clinical trial","volume":"147","author":"Guenther L","year":"2002","journal-title":"Br J Dermatol"},{"key":"ref99","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1111\/j.1365-2133.2007.08037.x","article-title":"Topical becocalcidiol for the treatment of psoriasis vulgaris: a randomized, placebo-controlled, double-blind, multicentre study","volume":"157","author":"Helfrich YR","year":"2007","journal-title":"Br J Dermatol"},{"key":"ref100","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/0190-9622(95)90186-8","article-title":"Calcipotriene ointment 0.005% for psoriasis: a safety and efficacy study. Calcipotriene Study Group","volume":"32","author":"Highton A","year":"1995","journal-title":"J Am Acad Dermatol"},{"key":"ref101","first-page":"348","article-title":"Evaluation of the efficacy and safety of clobetasol propionate spray in the treatment of plaque-type psoriasis","volume":"78","author":"Jarratt MT","year":"2006","journal-title":"Cutis"},{"key":"ref102","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1159\/000066440","article-title":"A New Calcipotriol\/Betamethasone Dipropionate Formulation (Daivobet<sup>TM<\/ sup>) Is an Effective Once-Daily Treatment for Psoriasis vulgaris","volume":"205","author":"Kaufmann R","year":"2002","journal-title":"Dermatology"},{"key":"ref103","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1111\/j.1365-2133.2004.05986.x","article-title":"Efficacy of once-daily treatment regimens with calcipotriol\/betamethasone dipropionate ointment and calcipotriol ointment in psoriasis vulgaris","volume":"150","author":"Kragballe K","year":"2004","journal-title":"Br J Dermatol"},{"key":"ref104","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1001\/archderm.1989.01670240047011","article-title":"Treatment of psoriasis by the topical application of the novel cholecalciferol analogue calcipotriol (MC 903)","volume":"125","author":"Kragballe K","year":"1989","journal-title":"Arch Dermatol"},{"key":"ref105","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/S0190-9622(83)70059-9","article-title":"Once-daily treatment of psoriasis with topical glucocorticosteroid ointments","volume":"8","author":"Lane AT","year":"1983","journal-title":"J Am Acad Dermatol"},{"key":"ref106","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1111\/j.1365-2133.1993.tb00237.x","article-title":"Topical calcitriol in the treatment of chronic plaque psoriasis: a double-blind study","volume":"128","author":"Langner A","year":"1993","journal-title":"Br J Dermatol"},{"key":"ref107","first-page":"428","article-title":"Calcitriol 3 microg\/g ointment in the management of mild to moderate plaque type psoriasis: results from 2 placebo-controlled, multicenter, randomized double-blind, clinical studies","volume":"6","author":"Lebwohl M","year":"2007","journal-title":"J Drugs Dermatol"},{"key":"ref108","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1046\/j.1365-4362.2002.01431.x","article-title":"A randomized, double-blind, placebo-controlled study of clobetasol propionate 0.05% foam in the treatment of nonscalp psoriasis","volume":"41","author":"Lebwohl M","year":"2002","journal-title":"Int J Dermatol"},{"issue":"2","key":"ref109","first-page":"57","article-title":"Efficacy and safety of fluticasone propionate 0.005% ointment in the treatment of psoriasis","volume":"57","author":"Olsen EA","year":"1996","journal-title":"Cutis"},{"key":"ref110","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1067\/mjd.2003.130","article-title":"Early onset of action and efficacy of a combination of calcipotriene and betamethasone dipropionate in the treatment of psoriasis","volume":"48","author":"Papp KA","year":"2003","journal-title":"J Am Acad Dermatol"},{"key":"ref111","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1111\/j.1365-2133.1996.tb07608.x","article-title":"Efficacy and safety of topical calcitriol (1,25-dihydroxyvitamin d3) for the treatment of psoriasis","volume":"134","author":"P\u00e8rez A","year":"1996","journal-title":"Br J Dermatol"},{"key":"ref112","first-page":"613","article-title":"Comparison of the antipsoriatic effect and tolerability of calcipotriol-containing products in the treatment of psoriasis vulgaris using a modified psoriasis plaque test","volume":"32","author":"Queille-Roussel C","year":"2012","journal-title":"Clin Drug Investig"},{"key":"ref113","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1080\/09546630701646156","article-title":"Efficacy, safety and quality of life of calcipotriol\/betamethasone dipropionate (Dovobet) versus calcipotriol (Daivonex) in the treatment of psoriasis vulgaris: a randomized, multicentre, clinical trial","volume":"18","author":"Saraceno R","year":"2007","journal-title":"J Dermatolog Treat"},{"key":"ref114","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1177\/120347540100500404","article-title":"Betamethasone valerate foam for treatment of nonscalp psoriasis","volume":"5","author":"Stein LF","year":"2001","journal-title":"J Cutan Med Surg"},{"key":"ref115","doi-asserted-by":"crossref","first-page":"13","DOI":"10.3109\/09546630903214175","article-title":"Treatment of plaque psoriasis with the two-compound product calcipotriol\/betamethasone dipropionate versus both monotherapies: an immunohistochemical study","volume":"21","author":"van der Velden HM1","year":"2010","journal-title":"J Dermatolog Treat"},{"key":"ref116","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1001\/archderm.134.9.1101","article-title":"Topical tacrolimus is not effective in chronic plaque psoriasis. A pilot study","volume":"134","author":"Zonneveld IM","year":"1998","journal-title":"Arch Dermatol"},{"key":"ref117","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1111\/bjd.16106","article-title":"Fumaric acid esters in combination with a 6-week course of narrowband ultraviolet B provides an accelerated response compared with fumaric acid esters monotherapy in patients with moderate-to-severe plaque psoriasis: a randomized prospective clinical study","volume":"178","author":"Tzaneva S","year":"2018","journal-title":"Br J Dermatol"},{"key":"ref118","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1111\/ijd.12444","article-title":"Comparative study of the effect of narrowband ultraviolet B phototherapy plus methotrexate vs. narrowband ultraviolet B alone and methotrexate alone in the treatment of plaque-type psoriasis","volume":"53","author":"Al-Hamamy HR","year":"2014","journal-title":"Int J Dermatol"},{"key":"ref119","doi-asserted-by":"crossref","first-page":"261","DOI":"10.3109\/09546634.2011.607795","article-title":"A randomized study comparing the combination of nbUVB and etanercept to etanercept monotherapy in patients with psoriasis who do not exhibit an excellent response after 12 weeks of etanercept","volume":"23","author":"Lynde CW","year":"2012","journal-title":"J Dermatolog Treat"},{"key":"ref120","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1111\/j.1365-2133.2008.08926.x","article-title":"Treatment with 311-nm ultraviolet B accelerates and improves the clearance of psoriatic lesions in patients treated with etanercept","volume":"160","author":"Wolf P","year":"2009","journal-title":"Br J Dermatol"},{"key":"ref121","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1111\/j.1600-0781.2011.00594.x","article-title":"311 nm ultraviolet B-accelerated response of psoriatic lesions in adalimumab-treated patients","volume":"27","author":"Wolf P","year":"2011","journal-title":"Photodermatol Photoimmunol Photomed"},{"key":"ref122","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1111\/1346-8138.12102","article-title":"Comparison of clinical effects of psoriasis treatment regimens among calcipotriol alone, narrowband ultraviolet B phototherapy alone, combination of calcipotriol and narrowband ultraviolet B phototherapy once a week, and combination of calcipotriol and narrowband ultraviolet B phototherapy more than twice a week","volume":"40","author":"Takahashi H","year":"2013","journal-title":"J Dermatol"},{"key":"ref123","doi-asserted-by":"crossref","first-page":"66","DOI":"10.4103\/ijmr.IJMR_249_16","article-title":"A non-inferiority randomized controlled clinical trial comparing Unani formulation & psoralen plus ultraviolet A sol in chronic plaque psoriasis","volume":"147","author":"Khanna N","year":"2018","journal-title":"Indian J Med Res"},{"key":"ref124","doi-asserted-by":"crossref","first-page":"221","DOI":"10.3109\/09546634.2015.1093588","article-title":"Broad-band UVB versus paint PUVA for palmoplantar psoriasis treatment","volume":"27","author":"Lozinski A","year":"2016","journal-title":"J Dermatolog Treat"},{"key":"ref125","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1046\/j.1365-2133.2003.05482.x","article-title":"A randomized controlled trial of narrowband ultraviolet B vs bath-psoralen plus ultraviolet A photochemotherapy for psoriasis","volume":"148","author":"Dawe RS","year":"2003","journal-title":"Br J Dermatol"},{"key":"ref126","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1080\/00015550310022916","article-title":"Randomized half-side comparison of narrowband UVB and trimethylpsoralen bath plus UVA treatments for psoriasis","volume":"84","author":"Snellman E","year":"2004","journal-title":"Acta Derm Venereol"},{"key":"ref127","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1001\/archderm.139.3.325","article-title":"Narrowband UV-B (TL-01) phototherapy vs oral 8-methoxypsoralen psoralen-UV-A for the treatment of chronic plaque psoriasis","volume":"139","author":"Markham T","year":"2003","journal-title":"Arch Dermatol"},{"key":"ref128","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/S0190-9622(99)70008-3","article-title":"A randomized comparison of narrow-band TL-01 phototherapy and PUVA photochemotherapy for psoriasis","volume":"41","author":"Gordon PM","year":"1999","journal-title":"J Am Acad Dermatol"},{"key":"ref129","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/j.1600-0781.2010.00525.x","article-title":"Bath psoralen+ultraviolet A photochemotherapy vs. narrow band-ultraviolet B in psoriasis: a comparison of clinical outcome and effect on circulating T-helper and T-suppressor\/cytotoxic cells","volume":"26","author":"Salem SA","year":"2010","journal-title":"Photodermatol Photoimmunol Photomed"},{"key":"ref130","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/j.1365-2133.1992.tb14815.x","article-title":"A comparison of the efficacy and relapse rates of narrowband UVB (TL-01) monotherapy vs. etretinate (re- TL-01) vs. etretinate-PUVA (re-PUVA) in the treatment of psoriasis patients","volume":"127","author":"Green C","year":"1992","journal-title":"Br J Dermatol"},{"key":"ref131","doi-asserted-by":"crossref","first-page":"589","DOI":"10.2340\/00015555-0529","article-title":"A randomized comparison of acitretinnarrow-band TL-01 phototherapy and acitretin-psoralen plus ultraviolet A for psoriasis","volume":"88","author":"Ozdemir M","year":"2008","journal-title":"Acta Derm Venereol"},{"key":"ref132","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1111\/j.1365-2230.2010.03874.x","article-title":"Narrowband ultraviolet B versus psoralen plus ultraviolet A therapy for severe plaque psoriasis: an Indian perspective","volume":"36","author":"Chauhan PS","year":"2011","journal-title":"Clin Exp Dermatol"},{"key":"ref133","doi-asserted-by":"crossref","first-page":"533","DOI":"10.4103\/0378-6323.69081","article-title":"Comparative evaluation of NBUVB phototherapy and PUVA photochemotherapy in chronic plaque psoriasis","volume":"76","author":"Dayal S","year":"2010","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"ref134","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1111\/j.1346-8138.2007.00306.x","article-title":"Comparison of the efficacy of local narrowband ultraviolet B (NB-UVB) phototherapy versus psoralen plus ultraviolet A (PUVA) paint for palmoplantar psoriasis","volume":"34","author":"Sezer E","year":"2007","journal-title":"J Dermatol"},{"key":"ref135","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/S0140-6736(16)32127-4","article-title":"An intensified dosing schedule of subcutaneous methotrexate in patients with moderate to severe plaque-type psoriasis (METOP): a 52 week, multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"389","author":"Warren RB","year":"2017","journal-title":"Lancet"},{"key":"ref136","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/j.jaad.2009.12.029","article-title":"Benefit-risk analysis of adalimumab versus methotrexate and placebo in the treatment of moderate to severe psoriasis: comparison of adverse event-free response days in the CHAMPION trial","volume":"63","author":"Reich K","year":"2010","journal-title":"J Am Acad Dermatol"},{"key":"ref137","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1111\/j.1365-2133.2007.08315.x","article-title":"Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION)","volume":"158","author":"Saurat JH","year":"2008","journal-title":"Br J Dermatol"},{"key":"ref138","doi-asserted-by":"crossref","first-page":"e305","DOI":"10.1111\/j.1468-3083.2012.04644.x","article-title":"Efficacy and safety of acitretin in three fixed doses of 25, 35 and 50 mg in adult patients with severe plaque type psoriasis: a randomized, double blind, parallel group, dose ranging study","volume":"27","author":"Dogra S","year":"2013","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref139","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1016\/S0190-9622(89)70138-9","article-title":"Side-effect profile of acitretin therapy in psoriasis","volume":"20","author":"Gupta AK","year":"1989","journal-title":"J Am Acad Dermatol"},{"key":"ref140","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1177\/039463201002300418","article-title":"Psoriasis relapse evaluation with week-end cyclosporine A treatment: results of a randomized, double-blind, multicenter study","volume":"23","author":"Colombo D","year":"2010","journal-title":"Int J Immunopathol Pharmacol"},{"key":"ref141","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1111\/j.1365-2133.1994.tb02935.x","article-title":"Efficacy and safety of oral cyclosporin A (CyA; Sandimmun) for long-term treatment of chronic severe plaque psoriasis","volume":"130","author":"Laburte C","year":"1994","journal-title":"Br J Dermatol"},{"key":"ref142","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/0190-9622(92)70012-5","article-title":"Cyclosporine in psoriasis: a multicenter dose-finding study in severe plaque psoriasis","volume":"26","author":"Christophers E","year":"1992","journal-title":"J Am Acad Dermatol"},{"key":"ref143","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1111\/j.1346-8138.2009.00748.x","article-title":"Adalimumab in Japanese patients with moderate to severe chronic plaque psoriasis: Efficacy and safety results from a Phase II\/III randomized controlled study","volume":"37","author":"Asahina A","year":"2010","journal-title":"J Dermatol"},{"key":"ref144","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.jaad.2011.07.034","article-title":"Moderate to severe plaque psoriasis with scalp involvement: a randomized, double-blind, placebo-controlled study of etanercept","volume":"67","author":"Bagel J","year":"2012","journal-title":"J Am Acad Dermatol"},{"key":"ref145","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/jdv.13746","article-title":"Efficacy and safety of adalimumab in Chinese patients with moderate-to-severe plaque psoriasis: results from a phase 3, randomized, placebo-controlled, double-blind study","volume":"31","author":"Cai L","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref146","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1016\/S0140-6736(00)04954-0","article-title":"Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial","volume":"357","author":"Chaudhari U","year":"2001","journal-title":"Lancet"},{"key":"ref147","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1111\/j.1365-2133.2008.08727.x","article-title":"Infliximab improves health-related quality of life in the presence of comorbidities among patients with moderate-to-severe psoriasis","volume":"159","author":"Feldman SR","year":"2008","journal-title":"Br J Dermatol"},{"key":"ref148","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1111\/j.1365-2133.2005.06510.x","article-title":"Infliximab treatment results in significant improvement in the quality of life of patients with severe psoriasis: a double-blind placebo-controlled trial","volume":"152","author":"Feldman SR","year":"2005","journal-title":"Br J Dermatol"},{"key":"ref149","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/j.jaad.2005.06.053","article-title":"Etanercept improves the health-related quality of life of patients with psoriasis: Results of a phase III randomized clinical trial","volume":"53","author":"Feldman SR","year":"2005","journal-title":"J Am Acad Dermatol"},{"key":"ref150","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.jaad.2006.05.027","article-title":"Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: Double-blind, randomized controlled trial and open-label extension study","volume":"55","author":"Gordon KB","year":"2006","journal-title":"J Am Acad Dermatol"},{"key":"ref151","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1111\/j.1365-2133.2011.10418.x","article-title":"Efficacy and safety of briakinumab vs. etanercept and placebo in patients with moderate to severe chronic plaque psoriasis","volume":"165","author":"Gottlieb AB","year":"2011","journal-title":"Br J Dermatol"},{"issue":"12","key":"ref152","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1001\/archderm.139.12.1627","article-title":"A randomized trial of etanercept as monotherapy for psoriasis","volume":"139","author":"Gottlieb AB","year":"2003","journal-title":"Arch Dermatol"},{"key":"ref153","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1067\/mjd.2003.307","article-title":"Infliximab monotherapy provides rapid and sustained benefit for plaque-type psoriasis","volume":"48","author":"Gottlieb AB","year":"2003","journal-title":"J Am Acad Dermatol"},{"issue":"7","key":"ref154","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1111\/j.1468-3083.2011.04082.x","article-title":"Impact of ustekinumab on health-related quality of life and sexual difficulties associated with psoriasis: results from two phase III clinical trials","volume":"25","author":"Guenther L","year":"2011","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref155","first-page":"1177","article-title":"Once weekly administration of etanercept 50 mg is efficacious and well tolerated in patients with moderate-to-severe plaque psoriasis: a randomized controlled trial with open-label extension","volume":"159","author":"van de Kerkhof PC","year":"2008","journal-title":"Br J Dermatol"},{"key":"ref156","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1111\/jdv.12046","article-title":"Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis treated for up to 5 years in the PHOENIX 1 study","volume":"27","author":"Kimball AB","year":"2013","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref157","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1111\/j.1365-2133.2012.10901.x","article-title":"Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial through up to 3 years","volume":"166","author":"Kimball AB","year":"2012","journal-title":"Br J Dermatol"},{"key":"ref158","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1111\/j.1365-2133.2005.06948.x","article-title":"Patient-reported outcomes of psoriasis improvement with etanercept therapy: results of a randomized phase III trial","volume":"153","author":"Krueger GG","year":"2005","journal-title":"Br J Dermatol"},{"key":"ref159","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1056\/NEJMoa1314258","article-title":"Secukinumab in Plaque Psoriasis - Results of Two Phase 3 Trials","volume":"371","author":"Langley RG","year":"2014","journal-title":"N Engl J Med"},{"key":"ref160","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.jaad.2009.09.014","article-title":"Ustekinumab significantly improves symptoms of anxiety, depression, and skin-related quality of life in patients with moderate-to-severe psoriasis: Results from a randomized, double-blind, placebo-controlled phase III trial","volume":"63","author":"Langley RG","year":"2010","journal-title":"J Am Acad Dermatol"},{"key":"ref161","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1016\/S0140-6736(08)60725-4","article-title":"Efficacy and safety of ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)","volume":"371","author":"Leonardi CL","year":"2008","journal-title":"Lancet"},{"key":"ref162","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1056\/NEJMoa030409","article-title":"Etanercept as monotherapy in patients with psoriasis","volume":"349","author":"Leonardi CL","year":"2003","journal-title":"N Engl J Med"},{"key":"ref163","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/j.1365-2133.2009.09491.x","article-title":"Ustekinumab improves health-related quality of life in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial","volume":"162","author":"Lebwohl M","year":"2010","journal-title":"Br J Dermatol"},{"key":"ref164","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.jaad.2009.09.040","article-title":"Efficacy and safety of adalimumab across subgroups of patients with moderate to severe psoriasis","volume":"63","author":"Menter A","year":"2010","journal-title":"J Am Acad Dermatol"},{"key":"ref165","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.jaad.2007.09.010","article-title":"Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial","volume":"58","author":"Menter A","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"ref166","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1111\/j.1346-8138.2012.01521.x","article-title":"Impact of ustekinumab on health-related quality of life in Japanese patients with moderate-to-severe plaque psoriasis: Results from a randomized, double-blind, placebo-controlled phase 2\/3 trial","volume":"39","author":"Nakagawa H","year":"2012","journal-title":"J Dermatol"},{"key":"ref167","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1111\/j.1365-2133.2005.06688.x","article-title":"A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction","volume":"152","author":"Papp KA","year":"2005","journal-title":"Br J Dermatol"},{"key":"ref168","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1111\/j.1365-2133.2006.07237.x","article-title":"Improvement in quality of life with infliximab induction and maintenance therapy in patients with moderate-to-severe psoriasis: a randomized controlled trial","volume":"154","author":"Reich K","year":"2006","journal-title":"Br J Dermatol"},{"key":"ref169","doi-asserted-by":"crossref","first-page":"337","DOI":"10.3109\/09546634.2010.499931","article-title":"Ustekinumab decreases work limitations, improves work productivity, and reduces work days missed in patients with moderate-to-severe psoriasis: results from PHOENIX 2","volume":"22","author":"Reich K","year":"2011","journal-title":"J Dermatolog Treat"},{"key":"ref170","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1111\/j.1365-2133.2007.08236.x","article-title":"Impact of adalimumab treatment on health-related quality of life and other patient-reported outcomes: results from a 16-week randomized controlled trial in patients with moderate to severe plaque psoriasis","volume":"158","author":"Revicki D","year":"2008","journal-title":"Br J Dermatol"},{"key":"ref171","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/1477-7525-6-75","article-title":"Adalimumab improves health-related quality of life in patients with moderate to severe plaque psoriasis compared with the United States general population norms: Results from a randomized, controlled Phase III study","volume":"6","author":"Revicki DA","year":"2008","journal-title":"Health Qual Life Outcomes"},{"key":"ref172","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1080\/09546630701646172","article-title":"Impact of adalimumab treatment on patient-reported outcomes: results from a Phase III clinical trial in patients with moderate to severe plaque psoriasis","volume":"18","author":"Revicki DA","year":"2007","journal-title":"J Dermatolog Treat"},{"key":"ref173","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1111\/j.1365-2133.2011.10419.x","article-title":"Efficacy and safety results from a phase III, randomized controlled trial comparing the safety and efficacy of briakinumab with etanercept and placebo in patients with moderate to severe chronic plaque psoriasis","volume":"165","author":"Strober BE","year":"2011","journal-title":"Br J Dermatol"},{"key":"ref174","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1111\/bjd.13469","article-title":"Long-term efficacy and safety of ustekinumab, with and without dosing adjustment, in patients with moderate-to-severe psoriasis: results from the PHOENIX 2 study through 5 years of follow-up","volume":"172","author":"Langley RG","year":"2015","journal-title":"Br J Dermatol"},{"key":"ref175","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1016\/S0140-6736(08)60726-6","article-title":"Efficacy and safety of ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)","volume":"371","author":"Papp KA","year":"2008","journal-title":"Lancet"},{"key":"ref176","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1111\/j.1346-8138.2011.01347.x","article-title":"Efficacy and safety of ustekinumab in Japanese patients with moderate-to-severe plaque-type psoriasis: long-term results from a phase 2\/3 clinical trial","volume":"39","author":"Igarashi A","year":"2012","journal-title":"J Dermatol"},{"key":"ref177","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.jdermsci.2011.05.005","article-title":"Efficacy and safety of ustekinumab for the treatment of moderate-to-severe psoriasis: A phase III, randomized, placebo-controlled trial in Taiwanese and Korean patients (PEARL)","volume":"63","author":"Tsai TF Ho JC","year":"2011","journal-title":"J Dermatol Sci"},{"key":"ref178","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1111\/1346-8138.14504","article-title":"Guselkumab, an anti-interleukin-23 monoclonal antibody, for the treatment of moderate to severe plaque-type psoriasis in Japanese patients: Efficacy and safety results from a phase 3, randomized, double-blind, placebo-controlled study","volume":"45","author":"Ohtsuki M","year":"2018","journal-title":"J Dermatol"},{"key":"ref179","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.jaad.2016.11.041","article-title":"Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial","volume":"76","author":"Blauvelt A","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"ref180","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/j.jaad.2017.06.153","article-title":"Efficacy and safety of ixekizumab for the treatment of moderate-to-severe plaque psoriasis: Results through 108 weeks of a randomized, controlled phase 3 clinical trial (UNCOVER-3)","volume":"77","author":"Blauvelt A","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"ref181","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/j.jaad.2018.05.032","article-title":"Maintenance of skin clearance with ixekizumab treatment of psoriasis: Three-year results from the UNCOVER-3 study","volume":"79","author":"Leonardi C","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"ref182","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1111\/bjd.15706","article-title":"Secukinumab sustains good efficacy and favourable safety in moderate-to-severe psoriasis after up to 3 years of treatment: results from a double-blind extension study","volume":"177","author":"Bissonnette R","year":"2017","journal-title":"Br J Dermatol"},{"key":"ref183","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1056\/NEJMoa0810652","article-title":"Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis","volume":"362","author":"Griffiths CE","year":"2010","journal-title":"N Engl J Med"},{"key":"ref184","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1056\/NEJMoa1503824","article-title":"Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis","volume":"373","author":"Lebwohl M","year":"2015","journal-title":"N Engl J Med."},{"key":"ref185","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/S0140-6736(15)60125-8","article-title":"Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials","volume":"386","author":"Griffiths CE","year":"2015","journal-title":"Lancet"},{"key":"ref186","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1111\/j.1365-2133.2011.10615.x","article-title":"Efficacy and safety of infliximab vs. methotrexate in patients with moderate-to-severe plaque psoriasis: results of an open-label, active-controlled, randomized trial (RESTORE1)","volume":"165","author":"Barker J","year":"2011","journal-title":"Br J Dermatol"},{"key":"ref187","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s12895-016-0048-z","article-title":"A multicenter, randomized, open-label pilot trial assessing the efficacy and safety of etanercept 50 mg twice weekly followed by etanercept 25 mg twice weekly, the combination of etanercept 25 mg twice weekly and acitretin, and acitretin alone in patients with moderate to severe psoriasis","volume":"16","author":"Lee JH","year":"2016","journal-title":"BMC Dermatol"},{"key":"ref188","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1111\/jdv.13990","article-title":"Treatment outcomes with ixekizumab in patients with moderate-to-severe psoriasis who have or have not received prior biological therapies: an integrated analysis of two Phase III randomized studies","volume":"31","author":"Gottlieb AB","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref189","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1111\/j.1365-2133.2010.09950.x","article-title":"Switching from etanercept to adalimumab is effective and safe: results in 30 patients with psoriasis with primary failure, secondary failure or intolerance to etanercept","volume":"163","author":"Van L\u00fcmig PP","year":"2010","journal-title":"Br J Dermatol"},{"key":"ref190","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1111\/j.1468-3083.2012.04496.x","article-title":"Adalimumab therapy for psoriasis in real-world practice: efficacy, safety and results in biologic-na\u00efve vs. non-na\u00efve patients","volume":"27","author":"van L\u00fcmig PP","year":"2013","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref191","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1111\/j.1468-3083.2010.03944.x","article-title":"Efficacy and safety of adalimumab in patients with psoriasis previously treated with anti-tumour necrosis factor agents: subanalysis of BELIEVE","volume":"25","author":"Ortonne JP","year":"2011","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref192","doi-asserted-by":"crossref","first-page":"319","DOI":"10.2165\/11310770-000000000-00000","article-title":"Efficacy and safety of etanercept in psoriasis after switching from other treatments: an observational study","volume":"10","author":"Mazzotta A","year":"2009","journal-title":"Am J Clin Dermatol"},{"key":"ref193","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.phrs.2017.04.014","article-title":"The acitretin and methotrexate combination therapy for psoriasis vulgaris achieves higher effectiveness and less liver fibrosis","volume":"121","author":"An J","year":"2017","journal-title":"Pharmacol Res"},{"key":"ref194","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/j.jaad.2006.01.004","article-title":"Methotrexate plus narrowband UVB phototherapy versus narrowband UVB phototherapy alone in the treatment of plaque-type psoriasis: a randomized, placebo-controlled study","volume":"54","author":"Asawanonda P","year":"2006","journal-title":"J Am Acad Dermatol"},{"key":"ref195","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1111\/j.1365-2230.2006.02153.x","article-title":"Methotrexate and ciclosporin combination for the treatment of severe psoriasis","volume":"31","author":"Aydin F","year":"2006","journal-title":"Clin Exp Dermatol"},{"key":"ref196","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1111\/bjd.12277","article-title":"Synergism between narrowband ultraviolet B phototherapy and etanercept for the treatment of plaque-type psoriasis","volume":"169","author":"Calzavara-Pinton PG","year":"2013","journal-title":"Br J Dermatol"},{"key":"ref197","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1111\/j.1365-2133.2011.10358.x","article-title":"Etanercept plus narrowband ultraviolet B phototherapy of psoriasis is more effective than etanercept monotherapy at 6 weeks","volume":"164","author":"Gambichler T","year":"2011","journal-title":"Br J Dermatol"},{"key":"ref198","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1111\/j.1365-2133.2008.08564.x","article-title":"Combining etanercept and acitretin in the therapy of chronic plaque psoriasis: a 24-week, randomized, controlled, investigator-blinded pilot trial","volume":"158","author":"Gisondi P","year":"2008","journal-title":"Br J Dermatol"},{"key":"ref199","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1111\/j.1365-2133.2012.11015.x","article-title":"A randomized, double-blind, placebo-controlled study to evaluate the addition of methotrexate to etanercept in patients with moderate to severe plaque psoriasis","volume":"167","author":"Gottlieb AB","year":"2012","journal-title":"Br J Dermatol"},{"key":"ref200","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1111\/j.1365-2133.1989.tb01354.x","article-title":"Combined treatment of psoriasis with acitretin and UVB phototherapy compared with acitretin alone and UVB alone","volume":"120","author":"Iest J","year":"1989","journal-title":"Br J Dermatol"},{"key":"ref201","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/0190-9622(91)70089-K","article-title":"Acitretin plus UVB therapy for psoriasis. Comparisons with placebo plus UVB and acitretin alone","volume":"24","author":"Lowe NJ","year":"1991","journal-title":"J Am Acad Dermatol"},{"key":"ref202","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1111\/j.1468-3083.2009.03486.x","article-title":"Methotrexate\/narrowband UVB phototherapy combination vs. narrowband UVB phototherapy in the treatment of chronic plaque-type psoriasis--a randomized single-blinded placebo-controlled study","volume":"24","author":"Mahajan R","year":"2010","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref203","doi-asserted-by":"crossref","first-page":"50","DOI":"10.3109\/09546634.2013.782094","article-title":"A retrospective analysis of combination methotrexate-cyclosporine therapy in moderate-severe psoriasis","volume":"25","author":"Mohanan S","year":"2014","journal-title":"J Dermatolog Treat"},{"key":"ref204","first-page":"320","article-title":"Impact of previous biologic use on the efficacy and safety of brodalumab and ustekinumab in patients with moderate-to-severe plaque psoriasis: integrated analysis of the randomized controlled trials AMAGINE-2 and AMAGINE-3","volume":"179","author":"Papp KA","year":"2018","journal-title":"Br J Dermatol"},{"key":"ref205","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1111\/j.1468-3083.2012.04611.x","article-title":"A randomized, \"head-to-head\" pilot study comparing the effects of etanercept monotherapy vs. etanercept and narrowband ultraviolet B (NB-UVB) phototherapy in obese psoriasis patients","volume":"27","author":"Park KK","year":"2013","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref206","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/0190-9622(91)70253-X","article-title":"Photochemotherapy for severe psoriasis without or in combination with acitretin: a randomized, double-blind comparison study","volume":"25","author":"Tanew A","year":"1991","journal-title":"J Am Acad Dermatol"},{"key":"ref207","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1111\/j.1365-2133.2011.10616.x","article-title":"Treatment with 311-nm ultraviolet B enhanced response of psoriatic lesions in ustekinumab-treated patients: a randomized intraindividual trial","volume":"166","author":"Wolf P","year":"2012","journal-title":"Br J Dermatol"},{"key":"ref208","doi-asserted-by":"crossref","first-page":"495","DOI":"10.2340\/00015555-0511","article-title":"The Combination of Etanercept and Methotrexate Increases the Effectiveness of Treatment in Active Psoriasis Despite Inadequate Effect of Methotrexate Therapy","volume":"88","author":"Zachariae C","year":"2008","journal-title":"Acta Derm Venereol"},{"key":"ref209","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.ijwd.2016.02.001","article-title":"Considerations on biologic agents in psoriasis with the new pregnancy lactation labeling rule","volume":"2","author":"Abrouk M","year":"2016","journal-title":"Int J Womens Dermatol"},{"key":"ref210","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.jaad.2011.07.039","article-title":"Review of treatment options for psoriasis in pregnant or lactating women: from the Medical Board of the National Psoriasis Foundation","volume":"67","author":"Bae YS","year":"2012","journal-title":"J Am Acad Dermatol"},{"key":"ref211","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s40257-015-0137-5","article-title":"Treating Psoriasis During Pregnancy: Safety and Efficacy of Treatments","volume":"16","author":"Bangsgaard N","year":"2015","journal-title":"Am J Clin Dermatol"},{"key":"ref212","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1097\/00007890-200104270-00006","article-title":"Pregnancy outcome after cyclosporine therapy during pregnancy: a meta-analysis","volume":"71","author":"Bar Oz B","year":"2001","journal-title":"Transplantation"},{"key":"ref213","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1093\/rheumatology\/keq185","article-title":"Etanercept concentrations in maternal serum, umbilical cord serum, breast milk and child serum during breastfeeding","volume":"49","author":"Berthelsen BG","year":"2010","journal-title":"Rheumatology (Oxford)"},{"key":"ref214","first-page":"1","article-title":"Systemic medications used in treatment of common dermatological conditions: safety profile with respect to pregnancy, breast feeding and content in seminal fluid","volume":"13","author":"Brown SM","year":"2018","journal-title":"J Dermatolog Treat"},{"key":"ref215","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1002\/pds.4261","article-title":"Pregnancy and infant outcomes including major congenital malformations among women with chronic inflammatory arthritis or psoriasis, with and without etanercept use","volume":"26","author":"Carman WJ","year":"2017","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"ref216","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1038\/jid.2010.392","article-title":"Safety of topical corticosteroids in pregnancy: a population-based cohort study","volume":"131","author":"Chi CC","year":"2011","journal-title":"J Invest Dermatol"},{"key":"ref217","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1007\/s40264-016-0431-z","article-title":"Pregnancy Outcomes in the Tofacitinib Safety Databases for Rheumatoid Arthritis and Psoriasis","volume":"39","author":"Clowse ME","year":"2016","journal-title":"Drug Saf"},{"key":"ref218","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1007\/s10103-011-0895-0","article-title":"Effect of narrowband ultraviolet B phototherapy on serum folic acid levels in patients with psoriasis","volume":"26","author":"El-Saie LT","year":"2011","journal-title":"Lasers Med Sci"},{"key":"ref219","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1002\/tera.1420470605","article-title":"Clinical teratology counseling and consultation case report: low dose methotrexate exposure in the early weeks of pregnancy","volume":"47","author":"Feldkamp M","year":"1993","journal-title":"Teratology"},{"key":"ref220","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1080\/000155599750010373","article-title":"A retrospective study of the teratogenicity of dermatological coal tar products","volume":"79","author":"Franssen ME","year":"1999","journal-title":"Acta Derm Venereol"},{"key":"ref221","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1097\/MCG.0b013e31825f2807","article-title":"Infliximab and adalimumab use during breastfeeding","volume":"46","author":"Fritzsche J","year":"2012","journal-title":"J Clin Gastroenterol"},{"key":"ref222","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.ejogrb.2004.11.035","article-title":"Pregnancy outcome after renal allograft transplantation: 15 years experience","volume":"121","author":"Ghanem ME","year":"2005","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"ref223","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1016\/S0140-6736(72)92319-7","article-title":"Transmission of a vitamin-D metabolite in breast milk","volume":"2","author":"Goldberg LD","year":"1972","journal-title":"Lancet"},{"key":"ref224","first-page":"867","article-title":"Teratogenic effects of vitamin A and its derivates","volume":"4","author":"Guillonneau M","year":"1997","journal-title":"Arch Pediatr"},{"key":"ref225","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1001\/archderm.1993.01680240060006","article-title":"Psoralen photochemotherapy (PUVA) and pregnancy","volume":"129","author":"Gunnarskog JG","year":"1993","journal-title":"Arch Dermatol"},{"key":"ref226","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1046\/j.1365-4362.2002.01464.x","article-title":"Dermatologic agents during pregnancy and lactation: an update and clinical review","volume":"41","author":"Hale EK","year":"2002","journal-title":"Int J Dermatol"},{"key":"ref227","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1586\/1744666X.2015.1037742","article-title":"Psoriasis during pregnancy: characteristics and important management recommendations","volume":"11","author":"Hoffman MB","year":"2015","journal-title":"Expert Rev Clin Immunol"},{"key":"ref228","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19051349","article-title":"The Use and Safety of TNF Inhibitors during Pregnancy in Women with Psoriasis: A Review","volume":"19","author":"Johansen CB","year":"2018","journal-title":"Int J Mol Sci"},{"key":"ref229","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1016\/0002-9378(72)90824-1","article-title":"Secretion of methotrexate into human milk","volume":"112","author":"Johns DG","year":"1972","journal-title":"Am J Obstet Gynecol"},{"key":"ref230","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1097\/MCG.0b013e31817f9367","article-title":"Absence of infliximab in infants and breast milk from nursing mothers receiving therapy for Crohn's disease before and after delivery","volume":"43","author":"Kane S","year":"2009","journal-title":"J Clin Gastroenterol"},{"key":"ref231","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/0002-9343(90)90522-F","article-title":"Outcome of first-trimester exposure to low-dose methotrexate in eight patients with rheumatic disease","volume":"88","author":"Kozlowski RD","year":"1990","journal-title":"Am J Med"},{"key":"ref232","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1590\/abd1806-4841.20153113","article-title":"Treatment of psoriasis and psoriatic arthritis during pregnancy and breastfeeding","volume":"90","author":"Kurizky PS","year":"2015","journal-title":"An Bras Dermatol"},{"issue":"5","key":"ref233","doi-asserted-by":"crossref","first-page":"2480","DOI":"10.1016\/S0041-1345(97)00458-2","article-title":"Analysis of 629 pregnancy outcomes in transplant recipients treated with Sandimmun","volume":"29","author":"Lamarque V","year":"1997","journal-title":"Transplant Proc"},{"key":"ref234","doi-asserted-by":"crossref","first-page":"401.e1","DOI":"10.1016\/j.jaad.2013.09.010","article-title":"Safety of dermatologic medications in pregnancy and lactation: Part I. Pregnancy","volume":"70","author":"Murase JE","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"ref235","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1136\/ard.2008.105924","article-title":"Etanercept during pregnancy and lactation in a patient with rheumatoid arthritis: drug levels in maternal serum, cord blood, breast milk and the infant's serum","volume":"68","author":"Murashima A","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"ref236","first-page":"599","article-title":"Multiple anomalies in a fetus exposed to low-dose methotrexate in the first trimester","volume":"99","author":"Nguyen C","year":"2002","journal-title":"Obstet Gynecol"},{"key":"ref237","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1097\/00007890-199801270-00019","article-title":"Breast-feeding during treatment with cyclosporine","volume":"65","author":"Nyberg G","year":"1998","journal-title":"Transplantation"},{"key":"ref238","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/s40264-013-0034-x","article-title":"Ciclosporin use during pregnancy","volume":"36","author":"Paziana K","year":"2013","journal-title":"Drug Saf"},{"key":"ref239","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1111\/ajd.12641","article-title":"Psoriasis in those planning a family, pregnant or breast-feeding. The Australasian Psoriasis Collaboration","volume":"59","author":"Rademaker M","year":"2018","journal-title":"Australas J Dermatol"},{"key":"ref240","first-page":"487","article-title":"Acitretin excretion into human breast milk","volume":"70","author":"Rollman O","year":"1990","journal-title":"Acta Derm Venereol"},{"key":"ref241","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/j.ad.2013.06.005","article-title":"Psoriasis in pregnancy: a review (II)","volume":"105","author":"Ruiz V","year":"2014","journal-title":"Actas Dermosifiliogr"},{"key":"ref242","series-title":"Drugs during pregnancy and lactation: treatment options and risk assessment","author":"Schaefer C","year":"2014","edition":"3rd ed"},{"key":"ref243","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1111\/j.1525-1470.2009.00880.x","article-title":"Uptake of pyrene in a breast-fed child of a mother treated with coal tar","volume":"26","author":"Scheepers PT","year":"2009","journal-title":"Pediatr Dermatol"},{"key":"ref244","first-page":"185","article-title":"Factitious hypertension with mineralocorticoid excess in an infant","volume":"38","author":"De Stefano P","year":"1983","journal-title":"Helv Paediatr Acta"},{"key":"ref245","doi-asserted-by":"crossref","first-page":"3085","DOI":"10.3748\/wjg.14.3085","article-title":"Is infliximab safe to use while breastfeeding?","volume":"14","author":"Stengel JZ","year":"2008","journal-title":"World J Gastroenterol"},{"key":"ref246","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1001\/archderm.1991.01680030067008","article-title":"Outcomes of pregnancies among women and partners of men with a history of exposure to methoxsalen photochemotherapy (PUVA) for the treatment of psoriasis","volume":"127","author":"Stern RS","year":"1991","journal-title":"Arch Dermatol"},{"key":"ref247","first-page":"83","article-title":"Psoriasis in pregnancy: challenges and solutions","volume":"5","author":"Vena GA","year":"2015","journal-title":"Psoriasis (Auckl)"},{"key":"ref248","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.1016\/j.jaad.2005.04.041","article-title":"Generalized pustular psoriasis of pregnancy treated with narrowband UVB and topical steroids","volume":"54","author":"Vun YY","year":"2006","journal-title":"J Am Acad Dermatol"},{"key":"ref249","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1111\/bjd.16901","article-title":"Secukinumab in pregnancy: outcomes in psoriasis, psoriatic arthritis and ankylosing spondylitis from the global safety database","volume":"179","author":"Warren RB","year":"2018","journal-title":"Br J Dermatol"},{"key":"ref250","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1111\/j.1346-8138.2011.01376.x","article-title":"Glucocorticosteroid-resistant pemphigoid gestationis: successful treatment with adjuvant immunoadsorption","volume":"39","author":"Westermann L","year":"2012","journal-title":"J Dermatol"},{"key":"ref251","doi-asserted-by":"crossref","first-page":"329","DOI":"10.3109\/09546634.2014.991673","article-title":"Safety of conventional systemic therapies for psoriasis on reproductive potential and outcomes","volume":"26","author":"Yiu ZZ","year":"2015","journal-title":"J Dermatolog Treat"},{"key":"ref252","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1136\/gutjnl-2012-302853","article-title":"Anti-TNF antibody-induced psoriasiform skin lesions in patients with inflammatory bowel disease are characterised by interferon-\u03b3-expressing Th1 cells and IL-17A\/ IL-22-expressing Th17 cells and respond to anti-IL-12\/IL-23 antibody treatment","volume":"63","author":"Tillack C","year":"2014","journal-title":"Gut"},{"key":"ref253","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/j.crohns.2011.10.007","article-title":"Induction of psoriasis with anti-TNF agents in patients with inflammatory bowel disease: a report of 21 cases","volume":"6","author":"Guerra I","year":"2012","journal-title":"J Crohns Colitis"},{"key":"ref254","doi-asserted-by":"crossref","first-page":"731","DOI":"10.2340\/00015555-2636","article-title":"Pattern and Severity of Psoriasiform Eruptions in Patients with Inflammatory Bowel Diseases, Arthritis or Skin Inflammatory Disorders Treated with TNF-alpha Inhibitors","volume":"97","author":"Darrigade AS","year":"2017","journal-title":"Acta Derm Venereol"},{"key":"ref255","first-page":"379","article-title":"Anti-TNF\u03b1 antibody-induced psoriasiform skin lesions in patients with inflammatory bowel disease: an Irish Cohort Study","volume":"110","author":"Kirthi Jeyarajah S","year":"2017","journal-title":"QJM"},{"key":"ref256","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1097\/MIB.0000000000000757","article-title":"Incidence, Clinical Characteristics, and Management of Psoriasis Induced by Anti-TNF Therapy in Patients with Inflammatory Bowel Disease: A Nationwide Cohort Study","volume":"22","author":"Guerra I1","year":"2016","journal-title":"Inflamm Bowel Dis"},{"key":"ref257","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1111\/j.1468-3083.2012.04582.x","article-title":"Induction and exacerbation of psoriasis with Interferon-alpha therapy for hepatitis C: a review and analysis of 36 cases","volume":"27","author":"Afshar M","year":"2013","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref258","doi-asserted-by":"crossref","first-page":"e78","DOI":"10.1097\/MJT.0b013e3181c6c0c2","article-title":"Psoriasis induced by losartan therapy: a case report and review of the literature","volume":"18","author":"Lamba G","year":"2011","journal-title":"Am J Ther"},{"key":"ref259","doi-asserted-by":"crossref","first-page":"e360","DOI":"10.1111\/j.1365-2230.2009.03315.x","article-title":"Psoriasiform fixed drug eruption caused by nimesulide","volume":"34","author":"Katoulis AC","year":"2009","journal-title":"Clin Exp Dermatol"},{"key":"ref260","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1001\/archderm.139.9.1223","article-title":"Psoriasis associated with rofecoxib","volume":"139","author":"Clark DW","year":"2003","journal-title":"Arch Dermatol"},{"key":"ref261","doi-asserted-by":"crossref","first-page":"217","DOI":"10.2340\/00015555-1855","article-title":"Use of aspirin, non-steroidal anti-inflammatory drugs, and acetaminophen (paracetamol), and risk of psoriasis and psoriatic arthritis: a cohort study","volume":"95","author":"Wu S","year":"2015","journal-title":"Acta Derm Venereol"},{"key":"ref262","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1111\/j.1365-2133.2008.08563.x","article-title":"Association between beta-blockers, other antihypertensive drugs and psoriasis: population-based case-control study","volume":"158","author":"Brauchli YB","year":"2008","journal-title":"Br J Dermatol"},{"key":"ref263","doi-asserted-by":"crossref","first-page":"346","DOI":"10.2340\/0001555564346348","article-title":"Psoriasis provoked by beta-blocking agents","volume":"64","author":"Arntzen N","year":"1984","journal-title":"Acta Derm Venereol"},{"key":"ref264","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1097\/JCP.0b013e31819a4b7c","article-title":"Lithium, antipsychotics, and risk of psoriasis","volume":"29","author":"Brauchli YB","year":"2009","journal-title":"J Clin Psychopharmacol"},{"key":"ref265","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S0165-0327(99)00064-6","article-title":"A control study of the cutaneous side effects of chronic lithium therapy","volume":"57","author":"Chan HH","year":"2000","journal-title":"J Affect Disord"},{"key":"ref266","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/S0190-9622(08)81761-6","article-title":"Angiotensin-converting enzyme inhibitors as possible exacerbating drugs in psoriasis","volume":"28","author":"Gilleaudeau P","year":"1993","journal-title":"J Am Acad Dermatol"},{"key":"ref267","first-page":"392","article-title":"Angiotensin-converting enzyme inhibitors and psoriasis","volume":"106","author":"Coulter DM","year":"1993","journal-title":"N Z Med J"},{"key":"ref268","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/0163-4453(92)93058-X","article-title":"Psoriasis worsened by antimalarial prophylaxis","volume":"24","author":"Vestey JP","year":"1992","journal-title":"J Infect"},{"key":"ref269","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1136\/bmj.299.6712.1400-a","article-title":"Risks and benefits of prophylactic antimalarial drugs","volume":"299","author":"Mallett R","year":"1989","journal-title":"BMJ"}],"container-title":["Anais Brasileiros de Dermatologia"],"original-title":[],"link":[{"URL":"http:\/\/www.scielo.br\/pdf\/abd\/v94n2s1\/0365-0596-abd-94-02-s1-0076.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T15:00:46Z","timestamp":1747666846000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.scielo.br\/scielo.php?script=sci_arttext&pid=S0365-05962019000700076&tlng=en"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4]]},"references-count":269,"journal-issue":{"issue":"2 suppl 1","published-online":{"date-parts":[[2019,4]]}},"alternative-id":["S0365-05962019000700076"],"URL":"https:\/\/doi.org\/10.1590\/abd1806-4841.2019940211","relation":{},"ISSN":["1806-4841","0365-0596"],"issn-type":[{"value":"1806-4841","type":"electronic"},{"value":"0365-0596","type":"print"}],"subject":[],"published":{"date-parts":[[2019,4]]}}}